Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.61 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704141 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3ASIC3 | |
| SCHEMBL6701144 | 0.78 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3CYP1A2CYP2D6 | |
| SCHEMBL7245886 | 0.66 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27474953 | 0.66 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6622031 | 0.65 | NOS1 (0.47) | NOS3NOS1ASIC3 | |
| SCHEMBL6621698 | 0.65 | NOS1 (0.64) | SLC6A4SLC6A3NOS3NOS1ASIC3 | |
| SCHEMBL9371327 | 0.64 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10326911 | 0.64 | SLC6A3 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10326624 | 0.64 | SLC6A3 (0.54) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10327324 | 0.64 | SLC6A3 (0.54) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | PFIZER INC | 2004-07-22 | — | — | US | disclosed |
| EP-0946512-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-08-01 | — | — | US | disclosed |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-03-14 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-6235750-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC | 2001-05-22 | — | — | US | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0946512-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024766-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | SLC6A2 176/4885SLC6A4 380/4885SLC6A3 326/4885 |
| US-20040142924-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | SLC6A2 176/4885SLC6A4 380/4885SLC6A3 326/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | SLC6A2 173/4885SLC6A4 332/4885SLC6A3 312/4885 |
| US-20020103227-A1 | 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | SLC6A2 176/4885SLC6A4 380/4885SLC6A3 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.